Pila Pharma AB (publ) (PILA.ST)
SEK 3.46
(13.44%)
SEK 3.46
(13.44%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.46 Million SEK | -22.21% |
| 2022 | 1.88 Million SEK | 161.49% |
| 2021 | 719.23 Thousand SEK | 0.0% |
| 2020 | - SEK | -100.0% |
| 2019 | 346.43 Thousand SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 341.5 Thousand SEK | 0.0% |
| 2024 Q1 | 341.5 Thousand SEK | -6.69% |
| 2023 Q2 | 301 Thousand SEK | -62.19% |
| 2023 Q4 | 366 Thousand SEK | 0.0% |
| 2023 Q1 | 796 Thousand SEK | 14.58% |
| 2023 Q3 | - SEK | -100.0% |
| 2023 FY | 1.46 Million SEK | -22.21% |
| 2022 Q4 | 694.73 Thousand SEK | 6.72% |
| 2022 Q2 | 651 Thousand SEK | 21.68% |
| 2022 FY | 1.88 Million SEK | 161.49% |
| 2022 Q1 | 535 Thousand SEK | -25.61% |
| 2022 Q3 | 651 Thousand SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 FY | 719.23 Thousand SEK | 0.0% |
| 2021 Q4 | 719.23 Thousand SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 FY | - SEK | -100.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2019 FY | 346.43 Thousand SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alzinova AB (publ) | 270 Thousand SEK | -441.859% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.762% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.879% |
| Saniona AB (publ) | 16.84 Million SEK | 91.312% |
| Simris Alg AB (publ) | 4.35 Million SEK | 66.398% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 48.157% |
| NextCell Pharma AB | 10.66 Million SEK | 86.282% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 86.972% |
| AcouSort AB (publ) | 10.55 Million SEK | 86.134% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 97.482% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.915% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.075% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 28.48 Million SEK | 94.864% |
| Kancera AB (publ) | 1.03 Million SEK | -41.355% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 27.357% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -2660.415% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 91.083% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.142% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | 3000.00 SEK | -48667.333% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.387% |
| Xintela AB (publ) | 78 Thousand SEK | -1775.667% |
| Ziccum AB (publ) | 3.74 Million SEK | 60.955% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -102.915% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | 5.54 Million SEK | 73.611% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -1025.4% |
| Intervacc AB (publ) | 8.01 Million SEK | 81.746% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 97.102% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 66.552% |
| Corline Biomedical AB | 25.03 Million SEK | 94.155% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 74.234% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 96.667% |
| Aptahem AB (publ) | 2.63 Million SEK | 44.386% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1800.026% |
| Fluicell AB (publ) | 3.33 Million SEK | 56.171% |
| Biovica International AB (publ) | 7.29 Million SEK | 79.931% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -21.614% |
| Abliva AB (publ) | 137 Thousand SEK | -967.898% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 97.46% |
| 2cureX AB (publ) | 155 Thousand SEK | -843.884% |
| I-Tech AB | 120.86 Million SEK | 98.79% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 98.909% |
| Cyxone AB (publ) | 5.14 Million SEK | 71.581% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 79.248% |
| Biosergen AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 1.44 Million SEK | -1.387% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 71.46 Million SEK | 97.953% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 95.846% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -6260.957% |